Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BDM-E: Phase I/II data

In a double-blind, Russian Phase I/II trial in 188 patients, BDM-E failed to significantly

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE